Polypid LTD

Ori Warshavsky, Chief Operating Officer - US of PolyPid Ltd., received 46,000 shares of common stock on May 11, 2026.

Jonathan Missulawin, Chief Financial Officer of PolyPid Ltd., received 49,000 shares of common stock on May 11, 2026.

Dalit Fellous Hazan, Deputy CEO, EVP, RD, CRA of PolyPid Ltd., received 75,000 shares of common stock on May 11, 2026.

Yechezkel Barenholz, a Director of PolyPid Ltd., received 9,132 shares of common stock on July 15, 2026.

Robert Benjamin Stein, a Director of PolyPid Ltd., received 9,132 shares of common stock on July 15, 2026.

Nir Dror-Darwish, a Director of PolyPid Ltd., received 9,132 shares of common stock on July 15, 2026.

An amended Schedule 13G filing reveals that Rodney Hodges and associated entities collectively hold a substantial 13.4% stake in PolyPid Ltd., including exercisable warrants.

Rosalind Advisors Inc. and related entities have filed a Schedule 13G, reporting a 9.9% beneficial ownership in PolyPid Ltd., with significant holdings subject to blocker provisions.

Rosalind Advisors Inc. and related entities report beneficial ownership of 9.9% of PolyPid Ltd. common stock, primarily through warrants.

Aurum Ventures M.K.I. Ltd. has increased its beneficial ownership in Polypid Ltd. to 24.4% through the exercise of warrants.

Rosalind Advisors and affiliated entities report a 9.9% beneficial ownership in PolyPid Ltd., including shares and warrants, subject to a 9.99% ownership blocker.

AIGH Capital Management LLC and Orin Hirschman have reported a 9.8% beneficial ownership stake in PolyPid Ltd. as of December 31, 2025.